PetIQ has expanded its pet health and wellness portfolio through the acquisition of MYOS Corp., adding the clinically studied Fortetropin® muscle health platform. The deal positions the company to compete in the growing market for mobility, recovery, and healthy aging products for companion animals.
- PetIQ has completed the acquisition of MYOS Corp., adding its Fortetropin® muscle health portfolio.
- The acquisition includes consumer supplements and veterinary-exclusive formulations.
- Fortetropin® is a patented bioactive ingredient supported by more than a dozen clinical studies.
- PetIQ said the acquisition strengthens its position in preventive pet health.
- Financial terms were not disclosed.
PetIQ has acquired MYOS Corp., bringing the company’s clinically studied Fortetropin® muscle health platform into its expanding portfolio of pet health and wellness products.
Expanding into muscle health
The transaction adds both consumer-facing supplements and veterinary-exclusive formulations centered on Fortetropin®, a patented bioactive ingredient designed to support muscle growth and preservation. According to PetIQ, the ingredient modulates myostatin and is intended to support muscle preservation, mobility, and recovery associated with aging, injury, or surgery. The technology has been studied in humans and companion animals, including dogs, cats, and horses.
PetIQ CEO Camillo Pane said the acquisition reflects growing demand for proactive approaches to pet mobility and healthy aging.
MYOS branding to continue
MYOS CEO Joe Mannello said PetIQ’s distribution and brand-building capabilities will help expand the reach of the company’s products. MYOS products and the Fortetropin® ingredient will continue to be marketed under their existing names.
Information sourced from the company’s press release.
